Myeloma
Myeloma multiple o simplemente myeloma es un typo de cancere del cellulas plasmic, un typo de leucocytos que normalment produci anticorpores.[1]
Sovente, in le principio, se notifica nulle symptoma.[2] Postea, dolor ossee, anemia, deficientia renal o infections recurrente pote occurrer.[2] Amyloidose pote esser un complication.[3]
Causas del multiple myeloma remane incognoscite.[4] Le factors de risco include obesitate, exposition al radiations, hereditate e alcun substantias chimic.[5][6][7] Le risco es augmentate in alcun empleos.[8] Es debite al exposition al solventes aromatic que poterea causar myelomas multiple.[9]
Se cura con chemotherapia. Un regimen de chemotherapia que se usa commun es le vincristina, adriamycina e dexamethasona. Le thalidomida, velcade, melphalan, prednisona e interferones etiam es utilisate.
Nota[modificar | modificar fonte]
- ↑ "Multiple myeloma" (July 2009). Lancet 374 (9686): 324–339. doi:. PMID 19541364.
- ↑ 2,0 2,1 Plasma Cell Neoplasms (Including Multiple Myeloma)—Patient Version (1980-01-01).
- ↑ Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version (July 29, 2016).
- ↑ (2014) World Cancer Report 2014. World Health Organization, Chapter 5.13. ISBN 978-92-832-0429-9.
- ↑ (2014) World Cancer Report 2014. World Health Organization, Chapter 2.3 and 2.6. ISBN 978-92-832-0429-9.
- ↑ Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (1980-01-01).
- ↑ (2013) Ferri's Clinical Advisor 2014 E-Book: 5 Books in 1. Elsevier Health Sciences, 726. ISBN 978-0-323-08431-4.
- ↑ "Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses" (September 2021). Journal of Clinical Medicine 10 (18): 4179. doi:. PMID 34575290.
- ↑ "Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma" (November 2018). Occupational and Environmental Medicine 75 (11): 798–806. doi:. PMID 30121582.